Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Endurance Bio Inc. has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 2 distinct examiners and 1 distinct art unit, so examiner responsibility is divided while the technical setting is shared.
BAUER, BRIANNA LEE is the busiest examiner, with 1 pending matter. Counsel should coordinate positions across the common art unit but prepare separate responses for the two examiner relationships.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BAUER, BRIANNA LEE | 1 | 66.7% | +0.0% |
| CHONG, YONG SOO | 1 | 43.8% | +41.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19019406 | THERAPEUTICALLY EFFECTIVE ORAL ADMINISTRATION OF A 2 ARYLBENZIMIDAZOLE | BAUER, BRIANNA LEE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18003153 | TREATMENT OF SYSTEMIC IMMUNE ACTIVATION SYNDROMES | CHONG, YONG SOO | 26d |
| Art Unit | Apps |
|---|---|
| 1623 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19019406 | THERAPEUTICALLY EFFECTIVE ORAL ADMINISTRATION OF A 2 ARYLBENZIMIDAZOLE | BAUER, BRIANNA LEE | 1623 | §102§103Other | Non-Final OA | — | Pending | Jan 13, 2025 |
| 18003153 | TREATMENT OF SYSTEMIC IMMUNE ACTIVATION SYNDROMES | CHONG, YONG SOO | 1623 | §103 | Non-Final OA | 26d | Pending | Dec 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEndurance Bio Inc. has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Brianna Lee Bauer has the most, with 1 of Endurance Bio Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
